In the Intuniv case, Faruqi & Faruqi represents a class of direct purchasers of Shire’s Intuniv (guanfacine), a prescription drug used to treat attention deficit hyperactivity disorder. The class also includes direct purchasers of generic versions of Intuniv from Actavis, Shire’s former co-defendant and alleged co-conspirator. Actavis has already settled for $19.9 million while litigation as to Shire remains ongoing. The complaint alleges that Shire entered a reverse payment patent settlement with Actavis to delay launching its first-filed generic to compete with Shire’s $300+ million a year Intuniv tablets. Such an agreement violates §§ 1 and 2 of the Sherman Act.
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 01/11/2017
Office
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771